SanegeneBio和Eli Lilly协作,利用有针对性的、每年两次的次皮治疗,对代谢性疾病进行RNAi疗法治疗。 SanegeneBio and Eli Lilly collaborate on RNAi therapies for metabolic diseases using targeted, twice-yearly subcutaneous treatment.

SanegeneBio与Eli Lilly合作,利用SanegeneBio的LEADTM交付技术开发了RNAi新陈代谢疾病的治疗方法,使目标明确、分层的行政管理能够达到每年两次的频率。 SanegeneBio has partnered with Eli Lilly to develop RNAi therapies for metabolic diseases using SanegeneBio’s LEAD™ delivery technology, enabling targeted, subcutaneous administration as infrequently as twice yearly. SanegeneBio领导发现和优化工作,Lilly则负责临床开发和商业化。 SanegeneBio leads discovery and optimization, while Lilly handles clinical development and commercialization. 该公司收到预付付款、股本和潜在的里程碑付款,总额达12亿美元,外加特许使用费。 The company receives an upfront payment, equity, and potential milestone payments totaling up to $1.2 billion, plus royalties. 合作推动治疗肥胖症和心肺紊乱等疾病。 The collaboration advances treatments for conditions like obesity and cardiometabolic disorders.